If you have spent any time reading about Semax, you have probably also seen its glossier cousin: N-Acetyl Semax Amidate, usually sold with a claim that it is "three to four times stronger" and lasts far longer. It is one of the most repeated numbers in the nootropic peptide space. It is also one of the least sourced. This post looks at what Semax research actually supports, where the potency claim comes from, why the chemistry behind the modified version raises a question nobody selling it tends to answer — and what Semax Australia status looks like under the TGA in 2026.

Short version up front: the two molecules are not interchangeable, the human record belongs to one of them, and the multiplier is a marketing figure, not a trial result.

What is Semax, and what is N-Acetyl Semax Amidate?

Semax is a synthetic heptapeptide: the ACTH(4–7) fragment Met-Glu-His-Phe with the biogenic tripeptide Pro-Gly-Pro (PGP) attached to the C-terminus. That tail was not decorative — it was added to slow proteolysis, because the bare ACTH fragment is destroyed almost instantly in plasma. The result is a peptide registered in Russia as nasal drops and listed on Russia's Vital and Essential Drugs list, used there in ischaemic stroke, transient ischaemic attack and optic nerve conditions.

N-Acetyl Semax Amidate (often "NA-Semax amidate") keeps that same seven-residue core but caps both ends: an acetyl group on the N-terminus, an amide on the C-terminus. Terminal capping is a standard medicinal-chemistry trick to blunt aminopeptidase and carboxypeptidase attack. The intent is a longer-lived molecule.

That is a reasonable design rationale. It is not the same thing as evidence that the capped version does more, in a living brain, than the uncapped one. You can read our compound background at /peptides/semax.

The 3–4x potency claim: where does it come from?

As far as we can find, it does not come from a published head-to-head. Comparison pages across the vendor and community ecosystem repeat the multiplier, and several of the more careful ones concede the point themselves: the figure circulates from retailer and forum sources, and direct comparisons of the two molecules in matched animal models with matched endpoints are sparse in the peer-reviewed literature.

There is also a conceptual slip buried in the claim. "More stable" and "more potent" are different properties. Blocking degradation changes how long a molecule persists; it does not change how strongly it engages a receptor. Treating a stability modification as a dose multiplier is an assumption, not a measurement — and in a compound where no human data exists for the modified form at all, it is an assumption with nothing underneath it.

The metabolite wrinkle: PGP is not an inert scrap

Here is the part that makes the capping question genuinely interesting rather than merely under-evidenced.

What the rat kinetics actually showed

A Russian group labelled Semax with tritium at the C-terminal proline and gave it intranasally to rats at 50 µg/kg. Two minutes after dosing, roughly 0.093% of the administered radioactivity per gram was recoverable from brain tissue — about 80% of it as intact Semax, the remainder as metabolites, with Pro-Gly-Pro the dominant breakdown product over time. This is a single small animal study from the mid-2000s, not a human pharmacokinetic programme, and it should be read that way.

The relevant point is what that metabolite does. Separate rat work in cerebral ischaemia models found that PGP on its own — not just the parent heptapeptide — altered transcription of neurotrophins and their receptors in ischaemic cortex and hippocampus. In other words, Semax's principal degradation product has documented activity of its own in the same models used to argue for Semax.

So a modification designed to stop Semax from being cleaved is, mechanistically, also a modification that reduces the supply of an apparently active metabolite. Whether that matters in practice is unknown — nobody has measured it. But it means the capped analogue cannot be assumed to be "Semax, only more so." It may be a different pharmacological object. All of this remains animal-model work; none of it has been demonstrated in people.

What the human evidence covers — and what it doesn't

The clinical record sits entirely with unmodified Semax, and it is thinner than its regulatory status in Russia implies. The trials are small by modern standards, largely Russian-language, frequently non-randomised or open-label, and rarely replicated by groups outside that network. There are no internationally registered trials of Semax. Nothing in that body of work transfers automatically to an acetylated, amidated analogue that has never been through it.

One more caution worth stating plainly for anyone browsing registry databases: peptide searches on ClinicalTrials.gov can surface fictional demonstration records with implausible sponsors. Check that the sponsor is a real, verifiable organisation before treating a registry hit as evidence.

Is Semax legal in Australia? The TGA angle

Semax is unscheduled in the Poisons Standard — which is routinely misread as "approved" or "legal to sell." It is neither. Semax is not on the Australian Register of Therapeutic Goods, making it an unapproved therapeutic good; importing, advertising or supplying it outside a TGA pathway such as the Special Access Scheme, Authorised Prescriber or a clinical trial is unlawful.

That distinction has sharpened. In 2026 the TGA elevated unapproved peptide products to a formal compliance and enforcement priority, flagging unlabelled vials and powders, and stating that products intercepted at the border which fail personal importation labelling requirements will be referred to the ABF for seizure and destruction. Enforcement options named include infringement notices, product seizures and civil or criminal penalties.

Worth noting for competitive athletes: Semax is not on the WADA 2026 Prohibited List, though specialists describe its status as unclear. That ambiguity does not extend cleanly to a chemically distinct capped analogue.

More compound profiles sit at /peptides.

What would change the picture

A single well-designed animal study dosing Semax and NA-Semax amidate side by side, at matched molar doses, with the same behavioural or ischaemia endpoints and metabolite sampling, would settle most of this. So would any human pharmacokinetic data on the capped form. Until one of those exists, the honest description of N-Acetyl Semax Amidate is "a plausible stability analogue of a modestly evidenced peptide, with no clinical record of its own."

Want these breakdowns as they publish? Join the free updates list at /#signup.

FAQ

What is Semax used for?

In Russia, where it is registered as nasal drops and listed on the Vital and Essential Drugs list, Semax is used in ischaemic stroke, transient ischaemic attack and certain optic nerve conditions. Most supporting trials are small, often non-randomised, and rarely replicated outside Russian research groups.

Is N-Acetyl Semax Amidate stronger than Semax?

There is no published head-to-head trial supporting the widely repeated "3–4x" figure — it circulates via vendor and community sources. The terminal caps are designed for proteolytic stability, which is a different property from receptor potency.

Is Semax legal in Australia?

Semax is unscheduled in the Poisons Standard but is not on the ARTG, making it an unapproved therapeutic good. Importing or supplying it outside TGA pathways is unlawful, and the TGA made unapproved peptides an enforcement priority in 2026.

Is Semax banned by WADA?

Semax is not listed on the WADA 2026 Prohibited List, although anti-doping specialists describe its status as unclear. Modified analogues such as N-Acetyl Semax Amidate are chemically distinct and carry no equivalent assurance.

Sources

This article is information only and not medical advice. Semax is an unapproved therapeutic good in Australia (registered in Russia, not on the ARTG); N-Acetyl Semax Amidate is an investigational analogue with no clinical record. retatrutide.net.au is independent and does not sell or source peptides.